Want to see GB:AOTI full AI Analyst Report?
Top Page
AOTI, Inc.
(LSE:AOTI)
Select Model
Select Model
Rating:54Neutral
Price Target:
43.00 p
▲(56.36% Upside)
Action:Reiterated
Date:01/15/26
The score is primarily constrained by ongoing losses and weak cash flow sustainability despite strong revenue growth and improved margins. Technicals are supportive but show signs of being stretched, and valuation is pressured by negative earnings with no dividend support.
Positive Factors
Revenue growth and gross margin expansion
Sustained top-line growth combined with a dramatic gross margin improvement implies stronger product-market fit and scalable unit economics. Over 2–6 months this supports reinvestment in R&D and sales, improving competitive positioning and long-term gross-profit resilience.
Negative Factors
Persistent unprofitability
Ongoing net losses erode retained capital and require external funding to sustain growth. Over months this limits the firm's ability to self-finance expansion, increases dilution or debt risk, and challenges the transition from margin improvements to consistent net profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and gross margin expansion
Sustained top-line growth combined with a dramatic gross margin improvement implies stronger product-market fit and scalable unit economics. Over 2–6 months this supports reinvestment in R&D and sales, improving competitive positioning and long-term gross-profit resilience.
Read all positive factors
AOTI, Inc. (AOTI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£66.47M
Dividend YieldN/A
Average Volume (3M)36.39K
Price to Earnings (P/E)120.8
Beta (1Y)0.12
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees85
SectorGeneral
Sector StrengthN/A
IndustryMedical - Specialties
Share Statistics
EPS (TTM)<0.01
Shares Outstanding106,359,160
10 Day Avg. Volume30,736
30 Day Avg. Volume36,392
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)8.47
Price to Sales (P/S)2.53
P/FCF Ratio-18.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)£87.03M
AOTI, Inc. Business Overview & Revenue Model
Company Description
AOTI, Inc. specializes in creating and marketing healthcare technologies specifically designed for treating persistent and hard-to-heal wounds. Among its offerings are the innovative Topical Wound Oxygen (TWO2) Therapy and the NEXA Negative Pressu...
How the Company Makes Money
AOTI generates revenue through multiple streams, including the sale of its proprietary optical systems and imaging software to healthcare providers, research institutions, and industrial clients. The company also engages in ongoing service contrac...
AOTI, Inc. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
55
Neutral
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 40.69M | 58.36M | 43.92M | 33.51M | 22.98M |
| Gross Profit | 21.30M | 51.35M | 37.59M | 2.86M | 45.36K |
| EBITDA | 4.30M | 2.64M | -4.28M | 3.14M | 16.52K |
| Net Income | 724.46K | -1.76M | -8.19M | -2.80M | 2.03M |
Balance Sheet | |||||
| Total Assets | 54.38M | 39.54M | 21.08M | 9.35M | 1.51M |
| Cash, Cash Equivalents and Short-Term Investments | 14.37M | 9.34M | 778.48K | 2.83M | 297.44K |
| Total Debt | 21.30M | 8.92M | 12.35M | 12.41M | 269.08K |
| Total Liabilities | 36.64M | 22.10M | 26.99M | 5.94M | 1.25M |
| Stockholders Equity | 17.74M | 17.44M | -5.91M | 760.20K | 1.52M |
Cash Flow | |||||
| Free Cash Flow | -7.35M | -7.85M | -2.76M | 1.77M | -428.43K |
| Operating Cash Flow | -5.79M | -5.91M | -1.45M | 2.77M | -46.07K |
| Investing Cash Flow | -1.52M | -1.94M | -1.59M | -3.13M | -904.53K |
| Financing Cash Flow | 10.54M | 16.41M | -202.81K | 5.72M | -692.04K |
AOTI, Inc. Technical Analysis
Positive
27.50
Price Trends
59.52
Positive
47.94
Positive
42.60
Positive
Market Momentum
1.28
Negative
68.30
Neutral
64.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AOTI, the sentiment is Positive. The current price of 27.5 is below the 20-day moving average (MA) of 60.13, below the 50-day MA of 59.52, and below the 200-day MA of 42.60, indicating a bullish trend. The MACD of 1.28 indicates Negative momentum. The RSI at 68.30 is Neutral, neither overbought nor oversold. The STOCH value of 64.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AOTI.
AOTI, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £113.18M | 55.96 | 3.01% | ― | 2.73% | -65.94% | |
59 Neutral | £123.43M | 1,327.27 | -3.95% | ― | 19.53% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | £66.47M | 120.82 | 4.12% | ― | ― | ― | |
50 Neutral | £25.91M | -12.20 | -55.91% | ― | 40.37% | -13.70% | |
45 Neutral | £10.05M | -0.33 | 425.97% | ― | ― | ― | |
44 Neutral | £8.58M | -0.40 | -122.54% | ― | 5.41% | 39.06% |
* General Sector Average
GB:AOTI
AOTI, Inc.
62.50
-27.50
-30.56%
GB:EKF
EKF Diagnostics Holdings
26.30
-0.70
-2.59%
GB:RENX
Renalytix
2.30
-4.70
-67.14%
GB:DXRX
Diaceutics
146.00
29.50
25.32%
GB:VRCI
Verici Dx Plc
0.38
-0.75
-66.67%
GB:ABDX
Abingdon Health PLC
10.25
3.25
46.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.